← Back to Episodes
PODCAST

Your Heart Remembers Your Depression (And Testosterone Myths Worth Dropping)

November 18, 2026·8:27·Episode 170

Quick Summary

A large 2026 cohort study found that women who had depression before menopause face meaningfully higher odds of cardiovascular disease afterward — and the two conditions may share more biological roots than medicine has traditionally acknowledged. The episode also digs into the growing use of testosterone therapy for women: what a recent JAMA piece and an FDA workshop revealed about the evidence, and why the common belief that testosterone causes hair loss in women is more complicated than most doctors realize.

Your Heart Remembers Your Depression (And Testosterone Myths Worth Dropping)

0:000:00

Key Takeaways

  • ✦Women who had depression before menopause had significantly higher cardiovascular disease risk after menopause, according to a large 2026 real-world cohort study — suggesting the two conditions may share underlying biological pathways, not just lifestyle factors.
  • ✦Testosterone use among women is rising, but the FDA has not approved any testosterone product specifically for women — meaning most prescriptions are off-label, and the long-term evidence is still catching up.
  • ✦An FDA public workshop in 2026 examined whether testosterone helps women with more than sexual function — areas like energy, mood, and cognition are being looked at, but the evidence there is still early.
  • ✦The belief that testosterone causes hair loss in women is not well supported by current evidence at the low doses used in female hormone therapy — but it remains a widespread assumption, even among clinicians.
  • ✦If you have a history of depression, that history is worth bringing up with whoever manages your heart health going into and through menopause — not because depression equals heart disease, but because the risk picture is more connected than the standard checkboxes suggest.

Episode Script

Thanks Toni. We've got a good one today.

So there's a study that just came out in October — published on PubMed, led by researcher Raju P — and it looked at a question that honestly should have been asked a long time ago. If a woman has depression before menopause, what happens to her heart health after menopause?

The study was large. Real-world data, which means it was pulled from actual patient records rather than a controlled trial setting. And what it found was that premenopausal depression was associated with a significantly higher risk of cardiovascular disease after menopause.

Now, before we go further, let's be precise about what that means and what it doesn't. This is an observational study — it shows a connection, not a cause. It doesn't prove that depression broke anything in the heart. It doesn't mean every woman who has ever had depression is now on a countdown. That's not what the data says, and it would be irresponsible to frame it that way.

What it does say is that the two things — depression and heart disease — are not as separate as medicine has traditionally treated them. For a long time, those were handled by completely different specialties, different checkboxes on your intake form, different conversations. Your mental health history over here, your cardiovascular risk over there. This study pushes back on that clean division.

The biological explanation researchers point to involves things like chronic inflammation, changes in the nervous system's regulation of the heart, and hormonal fluctuations — all of which can be part of depression and all of which can also affect cardiovascular health. Estrogen doesn't just affect hot flashes and sleep; it's involved in how blood vessels function. When estrogen drops at menopause, women who already had some underlying strain in those systems may be more vulnerable than women who didn't.

My position on this one is pretty clear: this finding matters, and it needs to change how we think about risk assessment. The standard cardiovascular risk tools ask about blood pressure, cholesterol, smoking, family history, weight, diabetes. Depression? Generally not on the list in any formal way. This study is a reasonable argument for changing that — not to alarm women, but to give a more complete picture.

If you have a history of depression — treated or untreated, one episode or recurring — that is worth bringing up with whoever manages your heart health, especially as you move through perimenopause and beyond. Not because depression equals a heart attack waiting to happen. But because the risk profile is more layered than the standard checklist captures, and your doctor should know.

The kind of evidence your doctor would look at on a tool like OpenEvidence increasingly reflects this kind of real-world cohort data alongside clinical trials. It's not fringe. It deserves a spot in the standard conversation.


Testosterone has been having a moment. That's not an overstatement — a recent JAMA Medical News piece looked at the rise in testosterone therapy for women, and it also covered an FDA public workshop that examined the current evidence on whether testosterone does anything useful for women beyond helping with low sexual desire.

That workshop is significant because it signals that the FDA is at least paying serious attention to this question. Right now, there is no FDA-approved testosterone product specifically for women. Zero. Which means that everything being prescribed — and prescriptions are rising — is off-label. Doctors are using products made for men, usually at much lower doses, and writing them for women. That happens in medicine all the time, and it's not automatically wrong. But it does mean the regulatory framework hasn't caught up with clinical practice.

What the FDA workshop was trying to get at is whether the evidence supports using testosterone for things beyond sexual function — areas like energy, mood, brain fog, and muscle maintenance. The honest answer right now is: maybe, but we don't know enough yet. The sexual function data is the strongest. For the other uses, the studies are smaller, shorter, and less consistent. That doesn't mean it doesn't work. It means we can't say confidently that it does.

What I find frustrating about the way testosterone for women gets discussed is that it swings between two equally unhelpful extremes. On one end, you have the wellness world treating it like a miracle — the missing piece, the thing that will give you your life back. On the other end, you have mainstream medicine being so cautious it borders on dismissive, partly because the trial data in women is genuinely thin and partly because there's a cultural discomfort with women using testosterone that has nothing to do with science.

The JAMA piece doesn't resolve that tension, but it does reflect that the FDA is trying to gather better evidence rather than just leaving the whole thing to clinical folklore. That's slow, but it's the right direction.


Connected to all of this is a conversation Dr. Kelly Casperson had on her podcast You Are Not Broken — episode 397, with Dr. Jessica Yih, a urologist and sexual health specialist at UC Irvine. The focus was testosterone, hair loss, and sexual health, and I think it's worth flagging because one of the most persistent reasons women say no to testosterone therapy is fear of losing their hair.

Dr. Yih's position, backed by what the evidence actually shows, is that testosterone at the low doses used in female hormone therapy is not well-established as a cause of hair loss in women. The concern is real in the sense that testosterone can convert to DHT, which is associated with androgenic hair thinning. But the doses women use are dramatically lower than what men use, and the clinical picture is more complicated than "testosterone equals hair loss."

The problem is that this belief — that testosterone will make your hair fall out — is widespread not just among patients but among clinicians. Doctors who haven't kept up with the sexual health literature are repeating this as though it's settled fact. It is not settled fact. It's a reasonable concern to monitor for, particularly in women who are already prone to androgenic hair loss. But blanket avoidance based on that fear, without a more individualized conversation? That's not evidence-based medicine. That's assumption-based medicine.

Dr. Yih also touched on something that doesn't get enough airtime, which is informed consent before pelvic surgery. Women often aren't told how procedures that affect the pelvic region — including certain hysterectomies, prolapse repairs, bladder surgeries — can affect sexual function afterward. That's a consent problem. You cannot make a genuinely informed decision about a surgery without knowing what it might change about your body.

The fact that it takes a urologist going on a podcast to say this out loud says a lot about the state of that conversation in mainstream gynecological and urological practice. It shouldn't be a podcast exclusive. It should be a standard part of surgical consultation.


Sources curated automatically by the Hot Flasher pipeline.

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.